Podcasts about renal disease

Commentary by Dr. Jian'an Wang.

Commentary by Dr. Yasushi Ueki.

In the October episode of Chattering with ISFM, host Nathalie Dowgray presents two detailed discussions on important feline health topics - gastrointestinal and renal health.First, Yaiza Gomez-Mejias interviews Sina Marsilio on feline chronic enteropathies, with a particular focus on gastrointestinal lymphoma and the diagnostic challenges of distinguishing small cell lymphoma from IBD. Marsilio discusses recent advances in the field, drawing from her recent work on the ACVIM consensus guidelines for ‘diagnosing and distinguishing low-grade neoplastic from inflammatory lymphocytic chronic enteropathies.' Later, Kelly St. Denis speaks with Jonathan Stockman about his JFMS Clinical Spotlight article, ‘Dietary Phosphorus and its Impact on Renal Disease in Cats'. They examine phosphorus metabolism, the risks associated with high-phosphorus diets, and effective strategies for managing phosphorus levels to support feline kidney health. For further reading material please visit:ACVIM consensus statement guidelines on diagnosing and distinguishing low-grade neoplastic from inflammatory lymphocytic chronic enteropathies in catsDietary Phosphorus and Renal Disease in cats: Where are we?For ISFM members, full recordings of each episode of the podcast is available for you to listen to at portal.icatcare.org. To become an ISFM member, or find out more about our Cat Friendly schemes, visit icatcare.orgHost: Nathalie Dowgray, BVSc, MANZCVS, PgDip, MRCVS, PhD, Head of ISFM, International Society of Feline Medicine, International Cat Care, Tisbury, Wiltshire, UK Speakers:Yaiza Gomez-Mejias, LdaVet MANZCVS (Medicine of Cats) CertAP (SAM-F) Acr AVEPA, ISFM Community Coordinator and Small Animal ClinicianSina Marsilio, Dr.med.vet., PhD, DACVIM (SAIM), DECVIM-CA, Assistant Professor of Medicine & Epidemiology at UC Davis.Kelly St. Denis, MSc, DVM, DABVP (Feline), Co-editor of the Journal of Feline Medicine and Surgery and JFMS Open Reports, St Denis Veterinary Professional Corporation, Powassan, Ontario, CanadaJonathan Stockman, DVM, DACVIM (Nutrition), Associate Professor in the Department of Clinical Veterinary Sciences & JFMS Author.

In this podcast episode, Lisa Jones, MA, RDN, LDN, FAND, interviews Kimberly Snodgrass, a renal care coordinator at Fresenius Medical Care, on how dieticians can help patients with renal disease manage minerals—such as potassium—in the their diet, how certain minerals affect renal patients, and what strategies can be implemented by dieticians to help manage key nutrients in the person's diet. This episode is part one of a three-part series.

GDP Script/ Top Stories for July 2nd   Publish Date:  July 2nd              From the Ingles Studio Welcome to the Gwinnett Daily Post Podcast. Today is Tuesday, July 2nd and Happy Birthday TO MLB player Jose Canseco. ***07.02.24 – BIRTHDAY – JOSE CANSECO*** I'm Bruce Jenkins and here are your top stories presented by KIA Mall of Georgia Buford Hall-of-Famer 'Pop' Carson Battling End Stage Renal Disease Top Spots to Celebrate Independence Day in Gwinnett County Greater Atlanta Christian Grad Makes U.S. Team All of this and more is coming up on the Gwinnett Daily Post podcast, and if you are looking for community news, we encourage you to listen daily and subscribe! Break 1: MOG   STORY 1: Buford Hall-of-Famer ‘Pop' Carson Battling End Stage Renal Disease   Michael "Pop" Carson, a prominent figure in Buford's sports history, is facing severe health challenges due to end-stage renal disease in central Florida. Carson, 63, played a crucial role in Buford's first state football championship in 1978 and later coached football and baseball for over 40 years. He launched a GoFundMe page to manage medical expenses, emphasizing gratitude for support. Despite health setbacks, including congestive heart failure, Carson remains hopeful and advocates for health awareness. His coaching career spanned various schools, impacting many students. Carson, known for his resilience, reflects on the importance of health and cherishes each day as a blessing. STORY 2: Here's Where to Celebrate Independence Day in Gwinnett County   From Stone Mountain Park to the charming streets of Lawrenceville, Gwinnett County is gearing up for an electrifying Independence Day. We're bringing you the lowdown on all the must-see events that will light up the sky and your hearts. Whether you're into patriotic fireworks, live music, or simply want to soak up the festive atmosphere, there's something here for everyone. Let's dive into the lineup and get you prepped for an unforgettable celebration! First off, head to Stone Mountain Park from July 1 to July 7 for nightly fireworks and a spectacular Drone & Light Show. On July 3, Lawrenceville brings you "Prelude to the Fourth!" with music and food trucks, while Norcross hosts "Red, White & Boom!" with live music and fireworks at Lillian Webb Park. On Independence Day itself, don't miss Lilburn's "Sparkle in the Park" and Snellville's "Star Spangled Snellville" with games, music, and more fireworks. Plus, Braselton offers a parade and festival, and Coolray Field presents "Fourth on the Field" with a kids' movie and fireworks at 9:15 p.m. STORY 3: Olympic Qualifier: Greater Atlanta Christian Grad Makes U.S. Team Jasmine Jones, a Greater Atlanta Christian graduate, secured her spot on the U.S. Olympic team by finishing third in the 400-meter hurdles on Sunday. Competing just after her senior season at USC, Jones clocked a personal best of 52.77 seconds. She trailed Sydney McLaughlin-Levrone, who set a new world record at 50.65 seconds, and her USC teammate Anna Cockerell, who finished second with 52.64 seconds. Jones' achievement not only earned her a place in the Olympics but also elevated her to the eighth spot on the all-time U.S. list for the event. We have opportunities for sponsors to get great engagement on these shows. Call 770.874.3200 for more info. We'll be right back Break 2: TOM WAGES   STORY 4: Georgia Gwinnett College's FAFSA center now open through Aug. 1 Georgia Gwinnett College's Free Application for Federal Student Aid (FAFSA) Completion Center will extend its operations until August 1 due to high demand. Since its launch in late April, the center, located conveniently on campus, has assisted over 400 students with their FAFSA applications. The FAFSA is crucial for determining federal aid eligibility, though the streamlined form introduced by the U.S. Department of Education in late 2023 has posed challenges. Kimberly Jordan, GGC's Executive Director of Financial Aid Services, highlighted the center's role not only in aiding applications but also in providing personalized support to students. The center remains committed to helping students start or continue their academic journey smoothly. STORY 5: One Man's Efforts to Stop Mulberry Cityhood Continues. What We Know. Stephen Hughes, an eastern Gwinnett resident, has filed a lawsuit against the state of Georgia in Fulton County Superior Court, challenging the constitutionality of legislation that established the city of Mulberry and scheduled its city council elections. This marks Hughes' third active lawsuit related to Mulberry's cityhood. His attorney, Allen Lightcap, argues that Senate Bill 333, which crafted Mulberry's charter and set the cityhood referendum, violates the Georgia Constitution. Hughes seeks declaratory and injunctive relief to halt the city council elections and prevent Governor Kemp from participating in any city transition. The core of Hughes' legal challenge focuses on provisions preventing Mulberry from levying property taxes and mandating specific municipal services, which he contends should be addressed through general legislation, not local mandates. Supporters of Mulberry cityhood assert these lawsuits are backed by developers opposing urban growth initiatives, following voter approval of the city in response to local development proposals. STORY 6: Community Fundraisers for New O'Kelly Memorial Library in Loganville The Friends of the O'Kelly Memorial Library group is actively fundraising to support the construction of a new library facility in Loganville, planned by the Azalea Regional Library System. With contributions from the state, Walton County, and Loganville totaling $5.7 million, the Friends group aims to raise an additional $2 million. This ambitious goal is crucial as the current library, recognized as Georgia's Library of the Year in 2021, has outgrown its 6,700-square-foot space. Challenges include insufficient room for programs and events, underscoring the need for the planned 12,000-square-foot facility which promises expanded services and community engagement opportunities. The Friends group recently received a $10,000 donation from Peach State Federal Credit Union, boosting their efforts towards this transformative project for Loganville. STORY 7: Supreme Court grants Trump partial immunity in Jan. 6 case   The Supreme Court, in a 6-3 decision, granted former President Trump significant immunity from criminal charges related to his actions during his presidency, effectively derailing a trial linked to the January 6 attack. While rejecting absolute immunity, the Court ruled that presidents cannot be prosecuted for official acts performed while in office. This decision sends the case back to lower courts and likely postpones any trial until after the November election, where Trump hopes to regain the presidency. Critics argue this delay hampers accountability, while Trump continues to face legal battles in multiple jurisdictions, including delays in Georgia and a pending sentencing in a separate case related to hush money payments. We'll have final thoughts after this.   Break 4: INGLES 10 Signoff – Thanks again for hanging out with us on today's Gwinnett Daily Post Podcast. If you enjoy these shows, we encourage you to check out our other offerings, like the Cherokee Tribune Ledger Podcast, the Marietta Daily Journal, or the Community Podcast for Rockdale Newton and Morgan Counties. Read more about all our stories and get other great content at www.gwinnettdailypost.com Did you know over 50% of Americans listen to podcasts weekly? Giving you important news about our community and telling great stories are what we do. Make sure you join us for our next episode and be sure to share this podcast on social media with your friends and family. Add us to your Alexa Flash Briefing or your Google Home Briefing and be sure to like, follow, and subscribe wherever you get your podcasts. Produced by the BG Podcast Network   Show Sponsors: www.ingles-markets.com  www.wagesfuneralhome.com www.kiamallofga.com     #NewsPodcast #CurrentEvents #TopHeadlines #BreakingNews #PodcastDiscussion #PodcastNews #InDepthAnalysis #NewsAnalysis #PodcastTrending #WorldNews #LocalNews #GlobalNews #PodcastInsights #NewsBrief #PodcastUpdate #NewsRoundup #WeeklyNews #DailyNews #PodcastInterviews #HotTopics #PodcastOpinions #InvestigativeJournalism #BehindTheHeadlines #PodcastMedia #NewsStories #PodcastReports #JournalismMatters #PodcastPerspectives #NewsCommentary #PodcastListeners #NewsPodcastCommunity #NewsSource #PodcastCuration #WorldAffairs #PodcastUpdates #AudioNews #PodcastJournalism #EmergingStories #NewsFlash #PodcastConversationsSee omnystudio.com/listener for privacy information.

The dialysis dilemma.

Is The NHIA's 6-Month Dialysis Care Support Sustainable?

Starting June 1st, the financial burden on renal patients will decline as the National Health Insurance Authority provides support. However, this assistance will only last for six months.

Join Tiffany and Kevin on this episode of "On The Record" as they sit down with special guest Reginald Ballard to discuss the urgent need for innovation in the pharmaceutical industry and the importance of acknowledging progress made in the fight against Chronic Kidney Disease (CKD). As the Texas Kidney Foundation (TKF) continues to lead the charge in early detection, education, and support, Reginal shares his insights on the power of community and the importance of amplifying positive stories. Don't miss this thought-provoking conversation on the future of healthcare and the impact of proactive approaches to addressing CKD. About the Texas Kidney Foundation: Texas Kidney Foundation (TKF) is dedicated to the early detection of Chronic Kidney Disease (CKD). Because we know the difficulties that go along with CKD, we use a proactive approach to address the disease. We believe early detection, education, and support will help Texans maintain their quality of life. TKF began because there was a need for patient services in the San Antonio and Rio Grande Valley regions because the local chapter of the nation's largest kidney foundation closed its doors and left the area. Unfortunately, they didn't take kidney disease with them. Luckily a tenacious transplant physician, Francis Wright, MD decided to create a foundation that would stand strong to serve our community, Texas Kidney Foundation (TKF). He gathered together a board of civic-minded people with a connection to renal disease. TKF has continued in that tradition. In 2017 under new leadership TKF began to emerge as a state and national leader within the Kidney space. TKF embarked on the first leg of a statewide campaign called the Kidney C.A.R.E. (Clinician and Adult Renal Education) Campaign. The campaign addresses the lack of knowledge about CKD because the disease is overwhelming families all over Texas. According to the Center for Disease Control, 1 out of 3 adults with diabetes have CKD. Every day in the U.S. 130 diabetics begin treatment for kidney failure. TKF is the voice leading the charge to stop the CKD pandemic. January 8, 2020, The State of Texas reestablished the previously abolished Texas Chronic Kidney Disease Task Force.See omnystudio.com/listener for privacy information.

Show notes at pharmacyjoe.com/episode913. In this episode, I’ll discuss the efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease. The post 913: Is there an efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease? appeared first on Pharmacy Joe.

Listen as Dr. London Smith (.com) and his producer Cameron discuss Intrinsic Renal Disease with special guest Mortimer Dipthong (Manny Silveira). Not so boring! https://www.patreon.com/join/jockdocpodcast Hosts: London Smith, Cameron Clark. Guest: Manny Silveira. Produced by: Dylan Walker Created by: London Smith

This recording features audio versions of January 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Association between End-Stage Renal Disease and Major Adverse Limb Events after Peripheral Vascular Intervention ReadPercutaneous CT-Guided Cryoablation for Locally Recurrent Prostate Cancer: Technical Feasibility, Safety, and Effectiveness ReadHydrogel Augmentation of the Lumbar Intervertebral Disc: An Early Feasibility Study of a Treatment for Discogenic Low Back Pain ReadProgression toward Vertebral Collapse of Vertebral Metastases Treated with Percutaneous Vertebroplasty: Rate and Risk Factors ReadA Pilot Study of Percutaneous Cholecystoenteric Anastomosis: A New Option for High-Risk Patients with Symptomatic Gallstones ReadMeasurement of the Tumor-to-Normal Ratio for Radioembolization of Hepatocellular Carcinoma: A Prospective Study Comparing 2-Dimensional Perfusion Angiography, Technetium-99m Macroaggregated Albumin, and Yttrium-90 SPECT/CT ReadJVIR and SIR thank all those who helped record this episode:Host:Rommell Noche, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutAudio editor:Siddhi Hegde, MBBS, Massachusetts General HospitalAbstract readers:Justin Cook, University of Central Florida College of MedicineColin Standifird, Kirk Kerkorian School of Medicine at University of Nevada, Las VegasAnna Hu, George Washington University School of Medicine and Health Sciences, D.C.Jack Ficke, Frank H. Netter MD School of Medicine at Quinnipiac University, ConnecticutEric Chang, MS, University of Illinois College of MedicineBrian Ng, Saint Louis University School of Medicine, Missouri©  Society of Interventional RadiologySupport the show

Dr. Peter A. McCullough is board certified in internal medicine, cardiovascular diseases, and clinical lipidology. He cares for advanced patients with common medical problems including heart and kidney disease, lipid disorders, and diabetes. He has become an expert on COVID-19 and vaccine illnesses.After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School. He went on to complete his internal medicine residency at the University of Washington, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan.Dr. McCullough has broadly published on a range of topics in medicine with > 1000 publications and > 660 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald's Heart Disease Textbook. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), and the European Medicines Agency. He has served as member or chair of data safety monitoring boards of dozens of randomized clinical trials.Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has >60 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in The Hill. Dr. McCullough has testified multiple times in the US Senate and in several State Senate Committees concerning early ambulatory treatment of high-risk patients with COVID-19 and the safety and theoretic efficacy of COVID-19 vaccination. Dr. McCullough welcomes post-COVID-19 patients into his practice and will help them through the range of post-infection complications and injuries resulting from COVID-19 vaccination.BOARD CERTIFICATIONS:Cardiovascular DiseaseAdvanced LipidologyInternal Medicine

There is an increasing awareness of non-tuberculous mycobacterium (NTM) disease as our populations ages and survival increases in chronic diseases due to new medical advances. NTM infections are often challenging to diagnose unless you are thinking about them as a possibility in your differential diagnosis. Therefore, there is an urgent need to identify population subgroups that are at increased risk for NTM infections. In this edition of the JIM podcast, Drs. Stephanie Baers and Sarah Tran discuss their recent manuscript: Non-tuberculous mycobacterial infections in patients with end-stage renal disease: Prevalence, risk factors, and mortality which can be found in the October 2023 issue of JIM.

Joining us on Well Said is Ms. Candice Halinski, a nurse practitioner who specializes in the care of patients with chronic and end-stage kidney disease, Deputy Chief Nursing Officer for Northwell Health Ambulatory Care and an Assistant Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. She will be talking about how traditionally, the only choices that patients with ESRD have been offered are a kidney transplant or chronic dialysis – however today there are different approaches to be considered.

Your MEM host Dr Cristina Cusu, Renal Registrar in Leicester, discussed progression to end stage renal failure, symptoms, how these patients are managed by the renal team and what you should be looking out for when you see these patients during on calls. Enjoy listening. 

Join Yvonne Brandenburg, RVT, VTS SAIM and Jordan Porter RVT, VTS SAIM as we talk about: Discover essential insights into managing Chronic Kidney Disease (CKD) in pets through proper nutrition, including therapeutic renal diets, protein restriction, mineral balance, vitamins, acid-base balance, and the role of fat, ensuring optimal care and improved quality of life for your furry companions.    Resources We Mentioned in the Show  "Nutritional Management of Renal Disease: An Evidence-Based Approach" from Today's Veterinary Practice: Link: https://todaysveterinarypractice.com/nutrition/nutritional-management-of-renal-disease-an-evidence-based-approach/#:~:text=Veterinary%20therapeutic%20renal%20diets%20are%20superior%20to%20conventional%20maintenance%20diets,antioxidants%20are%20beneficial%20for%20dogs Publisher: Today's Veterinary Practice "Chronic Renal Disease" from the UC Davis Veterinary Hospital's Animal Health Topics: Link: https://www.vetmed.ucdavis.edu/hospital/animal-health-topics/chronic-renal-disease Publisher: UC Davis Veterinary Hospital "Nutritional Management of Chronic Kidney Disease" from dvm360: Link: https://www.dvm360.com/view/nutritional-management-chronic-kidney-disease Publisher: dvm360 "Chronic Kidney Disease (CKD) in Dogs and Cats - Nutritional Management" from VIN (Veterinary Information Network): Link: https://www.vin.com/apputil/content/defaultadv1.aspx?pId=11258&id=3866140 Publisher: VIN (Veterinary Information Network)     Thanks so much for tuning in. Join us again next week for another episode!  Want to earn some RACE approved CE credits for listening to the podcast? You can earn between 0.5-1.0  hour of RACE approved CE credit for each podcast episode you listen to.    Join the Internal Medicine For Vet Techs Membership to earn and keep track of your continuing education hours as you get your learn on!   Join now! http://internalmedicineforvettechsmembership.com/   Get Access to the Membership Site for your RACE approved CE certificates Sign up at https://internalmedicineforvettechsmembership.com  Get Access to the Technician Treasure Trove  Sign up at https://imfpp.org/treasuretrove    Thanks for listening!  – Yvonne and Jordan     

In this episode, Robert S. Brown, Jr., MD, MPH; Nancy Reau, MD; and Eric, a person living with chronic hepatitis B, discuss solutions for overcoming barriers to HBV care in older adults, including:Awareness of HBV and CHB in older adultsUpdated HBV screening and vaccination recommendationsMonitoring of renal and bone diseaseAdjustment of monitoring and treatment as a person with HBV agesPresenters: Robert S. Brown, Jr., MD, MPHVincent Astor Distinguished Professor of MedicineChief, Division of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkNancy Reau, MDProfessor of MedicineChief, Section of HepatologyAssociate Director, Solid Organ TransplantationRichard B. Capps Chair of HepatologyRush University Medical CenterChicago, IllinoisEric, person living with chronic hepatitis BLink to downloadable slides: please link to VM404 downloadable slides when readyLink to program: bit.ly/3L3Kz6l

Scarlet fever is treatable with antibiotics, but in the middle of the 19th century, it was the leading cause of death in children in some parts of the world. Today, there are several ongoing mysteries about the disease. Research: Branswell, Helen. “Scarlet fever, a disease of yore, is making a comeback in parts of the world.” 11/27/2017. https://www.statnews.com/2017/11/27/scarlet-fever-cases/ Lamagni, Theresa et al. “Resurgence of scarlet fever in England, 2014–16: a population-based surveillance study.” The Lancet Infectious Diseases. Vol. 18, Issue 2. February 2018. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30693-X/fulltext?elsca1=tlpr Ferretti, Joseph and Werner Köhler. “History of Streptococcal Research.” From “Streptococcus pyogenes : Basic Biology to Clinical Manifestations.” Ferretti JJ, Stevens DL, Fischetti VA, editors. Oklahoma City (OK): University of Oklahoma Health Sciences Center; 2016. https://www.ncbi.nlm.nih.gov/books/NBK333430/ Doherty Institute. “Scarlet fever is on the rise, after being almost eradicated by the 1940s.” 10/6/2020. https://www.doherty.edu.au/news-events/news/scarlet-fever-is-on-the-rise-after-being-almost-eradicated-by-the-1940s Potter, Christina. “Scarlet Fever Makes a Comeback.” Outbreak Observatory. Johns Hopkins. 12/12/2019. https://www.outbreakobservatory.org/outbreakthursday-1/12/12/2019/scarlet-fever-makes-a-comeback Lynskey, Nicola N. et al. “Emergence of dominant toxigenic M1T1 Streptococcus pyogenes clone during increased scarlet fever activity in England: a population-based molecular epidemiological study.” The Lancet Infectious Diseases. Vol. 19, Issue 11. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30446-3/fulltext Tatiana Ninkov and Mike Cadogan, "Second disease," In: LITFL - Life in the FastLane, Accessed on January 25, 2023, https://litfl.com/second-disease/. Bright, Richard. "Dr. Bright on Renal Disease.” From Guy's Hospital reports. ser.1 v.1 1836. https://babel.hathitrust.org/cgi/pt?id=iau.31858046169490&view=1up&seq=392&skin=2021 Ledford, Heidi. “Why is strep A surging — and how worried are scientists?” 12/9/2022. https://www.nature.com/articles/d41586-022-04403-y Thomas Sydenham, ""On Scarlet Fever" [Excerpt]," in Children and Youth in History, Item #156, https://cyh.rrchnm.org/items/show/156 (accessed August 10, 2021). Annotated by Lynda Payne Klein, E. “The Etiology of Scarlet Fever.” Proceedings of the Royal Society of LondonVolume 42, Issue 251-257. https://royalsocietypublishing.org/doi/epdf/10.1098/rspl.1887.0030 Duncan CJ, Duncan SR, Scott S. The dynamics of scarlet fever epidemics in England and Wales in the 19th century. Epidemiol Infect. 1996 Dec;117(3):493-9. doi: 10.1017/s0950268800059161. PMID: 8972674; PMCID: PMC2271647. Klass, Perri. “Fever Dreams.” Harvard Medicine. Autumn 2022. https://hms.harvard.edu/magazine/handed-down/fever-dreams Davenport, Romola J. “Urbanization and mortality in Britain, c. 1800–50.” Economic History Review. 2/21/2020. https://onlinelibrary.wiley.com/doi/10.1111/ehr.12964 Thomson, Arthur S. et al. “History of the First Epidemic of Scarlet Fever which Prevailed in Auckland, New Zealand, During the Year 1848.” The Lancet. Vol. 55, Issue 1376. January 12, 1850. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)88319-2/fulltext Kaiser, Albert D. “Scarlet Fever.” The American Journal of Nursing , Jun., 1915, Vol. 15, No. 9 (Jun., 1915). Via JSTOR. https://www.jstor.org/stable/3404148 Eyler, John M. “The Epidemiology of Milk-borne Scarlet Fever: The Case of Edwardian Brighton.” American Journal of Public Health. May 1986, Vol. 76, No. 5. Wilson, Leonard G. “The Historical Riddle of Milk-borne Scarlet Fever.” Bulletin of the History of Medicine. Fall 1986. Vol. 60, No. 3. Via JSTOR. https://www.jstor.org/stable/44442285 Scamman, Clarence L. “Milk-Borne Septic Sore Throat and Scarlet Fever.” American Journal of Public Health. December 1929. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1581415/ Lee, Charles A. “Notes on the History and Pathology of Scarlatina.” Boston Medical Journal. 7/22/1835. Dick, George F. and Gladys R. Dick. “Immune Reactions in Scarlet Fever.” The Journal of Infectious Diseases, Vol. 19, No. 2 (Aug., 1916).” Via JSTOR. https://www.jstor.org/stable/30080317 Radikas, Regina and Cindy Connolly. “Young Patients in a Young Nation; Scarlet Fever in Early Nineteenth Century Rural New England.” Pediatric Nursing. January-February 2007. Rolleston, J.D. “The History of Scarlet Fever.” The British Medical Journal. 11/24/1928. See omnystudio.com/listener for privacy information.

Dr. Peter A. McCullough, one of the if not the *1 Cardiologist in the world https://www.petermcculloughmd.com , https://couragetofacecovid.com Dr. McCullough has broadly published on a range of topics in medicine with 1000 publications and 660 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald's Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster. Stay In touch with Dr. Peter A. McCullough : https://petermcculloughmd.substack.com https://www.heartplace.com https://podcasts.apple.com/us/podcast/the-mccullough-report/id1562849542 https://www.petermcculloughmd.com John Leake - Author of one of 3 best-selling books, Peter and John have a follow-up in the works to The Courage to Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex, now available in hardcover https://couragetofacecovid.com John Leake studied history and philosophy with Sir Roger Scruton at Boston University, in which he has received an M.A. in. John r went to Vienna, Austria on a graduate school scholarship and ended up living in the city for over a decade, working as a freelance writer and translator. John has released 3 books, all bestsellers, one of which with Dr. Peter A. Mccullough. There is so much more to John Leake. Stay in touch with John Leake : Book website: https://couragetofacecovid.com Substack: https://petermcculloughmd.substack.com

In this episode of our series focused on vascular surgery, host Dr. Rick Greene speaks with vascular surgeon Dr. Britt Tennessean about the clinical features and important management aspects of mesenteric and renal vascular disease. Britt H. Tonnessen, MD, FACS, is Associate Professor of Surgery, Division of Vascular Surgery & Endovascular Therapy; Associate Program Director, Vascular Integrated Residency, Yale University School of Medicine. Learn more about Selected Readings in General Surgery, an American College of Surgeons publication that highlights highly relevant and practice-changing information from the world's most prominent medical journals.   #SurgicalReadings #SRGS

In this podcast Dr Cassi talks to Dr. Tanner Slead about the current knowledge of congenital renal disease in dogs. Known causes, common clinical manifestations, diagnosis, treatment, and prognosis are all discussed. Elective surgery implications are also covered.

In his role as Strive Health's Vice President of Strategy & Development, Jackson Brasher draws on more than 15 years of experience to lead Strive Health's system team in their company mission to transform kidney care.Before joining the leadership team at Strive, Jackson held corporate strategy and business development roles at The Advisory Board Company, Trilliant Health, and Cardinal Health –  working with hospitals, health systems, and provider practices across the country on various innovation and growth initiatives. Jackson holds a B.A. from the University of Virginia and an M.B.A. from Duke. A Nashville native, Jackson enjoys spending time with his wife, daughter and the family's playful black lab. Outside of the office, he can be found on the lake, at a concert, or planning his next big trip. John Marchica, CEO, Darwin Research GroupJohn Marchica is a veteran health care strategist and CEO of Darwin Research Group. He is leading ongoing, in-depth research initiatives on integrated health systems, accountable care organizations, and value-based care models. He is a faculty associate in the W.P. Carey School of Business and the graduate College of Health Solutions at Arizona State University.John did his undergraduate work in economics at Knox College, has an MBA and M.A. in public policy from the University of Chicago, and completed his Ph.D. coursework at The Dartmouth Institute. He is an active member of the American College of Healthcare Executives and is pursuing certification as a Fellow. About Darwin Research GroupDarwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin's client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.

This week, please join authors Kevin Roedl and Sebastian Wolfrum, as well as Associate Editor Mark Link as they discuss the article "Temperature Control After In-Hospital Cardiac Arrest: A Randomized Clinical Trial." Dr. Carolyn Lam: Welcome to Circulation on the Run, your weekly podcast summary, and backstage pass to the Journal and its editors. We are your cohosts. I'm Dr. Carolyn Lam, Associate Editor from the National Heart Center, and Duke National University of Singapore. Dr. Greg Hundley: And I'm Dr. Greg Hundley, Associate Editor and Director of the Pauley Heart Center at VCU Health in Richmond, Virginia. Well, Carolyn, this week's feature, very interesting, a randomized clinical trial of temperature control after in-hospital cardiac arrest. But before we get to that exciting study, let's grab a cup of coffee, and jump in and discuss some of the other articles in the issue. Carolyn, would you like to go first? Dr. Carolyn Lam: Yes. Starting with a great quiz. So Greg, which is better? How about this? It's multiple choice. Is it A; transradial, or B; transfemoral access, in terms of post-procedural mortality? Dr. Greg Hundley: I'm going to go with transradial. It has been, hopefully, I'm okay on this. It just seems so many fewer complications. Dr. Carolyn Lam: But that's exactly that we need to meta-analyze the studies that have been done. Exactly what this paper did, led by Professor Valgimigli, from USI in Lugano, Switzerland. So what they did is, they performed an individual patient data meta-analysis of 21,600 patients, enrolled in seven multi-center randomized control trials, comparing the transradial with transfemoral access, among patients undergoing coronary angiography with or without PCI. And they found that transradial access was associated with a lower incidence of the primary outcome of all-cause mortality, and the co-primary outcome of major bleeding at 30 days, compared to transfemoral access. There was also evidence for reductions in major adverse cardiac and cerebral vascular events, net adverse clinical events, vascular complications, excess site bleeding, and blood transfusion. MI, stroke, and stent thrombosis, did not differ. And crossover was higher in the transradial access group. At predefined subgroup analysis, the authors confirmed that the benefit observed the transradial group was generally consistent across the majority of pre-specified subgroups, except for those with significant baseline anemia. Patients with baseline anemia appear to derive a substantial mortality benefit with transradial access rather than transoral access, compared to those with mild or no anemia. So, the authors concluded, that the meta-analysis provides evidence that transradial access should be considered the preferable access site for PCI, in patients with acute coronary syndrome, supporting most recent recommendations on the preferential use of this radial approach. So you were right, Greg. Dr. Greg Hundley: Very nice, Carolyn. A really important piece of science to disclose to our listeners, in that hurried state, and moving quickly door to balloon times, et cetera. And here we find another positive outcome in study result for transradial approaches. Well Carolyn, as we know, my next paper, it's really going to come to us from the world of preclinical science. And it pertains to hypertension, which is a common cardiovascular disease, and is related to both genetic and environmental factors. But the mechanisms linking the interplay between the domains of genetics and the environment have not been well studied. Now, DNA methylation, a classical epigenetic modification, not only regulates gene expression, but is also quite susceptible to environmental factors. Thereby, linking environmental factors to genetic modifications. So therefore, Carolyn, these authors, including Professor Jingzhou Chen, from Fuwai Hospital, National Center for Cardiovascular Diseases, and the Chinese Academy of Medical Sciences, and the Peking Union Medical College, and their colleagues, felt that screening differential genomic DNA methylation, in subjects with hypertension, would be important for investigating this genetic environment interplay in hypertension. So this study, Carolyn, like many from the world of preclinical science and circulation, incorporated both human and animal model subjects. Methodologically differential genomic DNA methylation in hypertensive, pre-hypertensive, and healthy control individuals, was screened using the Illumina 450K BeadChip, and then verified by pyrosequencing. Plasma oviduct glycoprotein 1, or OVGP1 levels, were determined using an enzyme-linked immunosorbent assay. And OVGP1 transgenic and knockout mice were generated to analyze the function of OVGP1. Dr. Carolyn Lam: Wow. Nice approach, Greg. And what did the authors find? Dr. Greg Hundley: Right, Carolyn. These authors found a hypomethylated site at cg20823859 in the promoter region of OVGP1, and the plasma OVGP1 levels were significantly increased in hypertensive patients. This finding indicates that OVGP1 is associated with hypertension. Now Carolyn, in OVGP1 transgenic mice, OVGP1 over expression caused an increase in blood pressure. Also, dysfunctional vasoconstriction, and vasodilation, remodeling of the arterial walls, and increased vascular superoxide stress and inflammation. And these phenomenon were exacerbated by angiotensin II infusion. In contrast, OVGP1 deficiency, attenuated angiotensin II induced vascular oxidase, stress, inflammation, and collagen deposition. Now pull down, and co-immunoprecipitation assays showed that myosin heavy chain 2A, or MYH9, interacted with OVGP1. Whereas, inhibition of MYH9 attenuated OVGP1 induced hypertension and vascular remodeling. Dr. Carolyn Lam: So Greg, let me try to summarize, is that okay? So hypomethylation, at that specific site in the promoter region of the OVGP1 gene, is associated with hypertension, and induces its upregulation. The interaction of this OVGP1 with myosin heavy chain 2A contributes to vascular remodeling and dysfunction. And so, OVGP1 is a pro hypertensive factor, that promotes vascular remodeling by binding to this myosin heavy chain. So, really cool stuff. Thanks for teaching us. Dr. Greg Hundley: Very good. Dr. Carolyn Lam: Well thanks so much, Greg. And we go back to the clinical world now, and ask the question, what is the efficacy and safety of prophylactic full dose anticoagulation and antiplatelet therapy, in critically ill COVID-19 patients? So I'm going to tell you the results of the COVID-PACT trial. And this was a multi-center, two-by-two factorial, open label, randomized controlled trial, with blinded endpoint adjudication in 390 ICU level patients. So, severely ill patients with COVID-19, from 34 US centers. Patients were randomized to a strategy of full dose anticoagulation, or standard dose prophylactic anticoagulation. And in the absence of an indication for antiplatelet therapy, patients were additionally randomized to either clopidogrel or no antiplatelet therapy. Dr. Greg Hundley: Ah, Carolyn. So what did they find? Dr. Carolyn Lam: Full dose anticoagulation substantially reduced the proportion of patients experiencing a venous or arterial thrombotic event, and there was no benefit from treatment with clopidogrel. Severe bleeding events were rare, but numerically increased in patients on full dose versus standard dose prophylactic anticoagulation, without any fatal bleeding events, GUSTO moderate or severe bleeding was so significantly increased with full dose anticoagulation, but with no difference in all-cause mortality. So in summary, in a population of critically ill patients with COVID-19, a strategy of prophylaxis with full dose, versus standard dose prophylactic anticoagulation, but not the addition of clopidogrel, reduced thrombotic complications, with an increased risk of bleeding, driven primarily by transfusions in hemodynamically stable patients, with no apparent excess in mortality. Dr. Greg Hundley: Very nice, Carolyn. What a important piece of information, as many of us around the world are taking care of critically ill patients with COVID-19. Well, how about we see what is in the mail bag this week? So first, Carolyn, there's a Frontiers piece by Dr. Packer, entitled, “Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 inhibitors, and Reaffirmation of the Nutrient Deprivation Signaling Autophagy Hypothesis.” Next, there's a Research Letter, from Professor Airaksinen entitled, “Novel Troponin Fragmentation Assay to Discriminate Between Troponin Elevations in Acute Myocardial Infarction and End-stage Renal Disease.” Carolyn, there's another Research Letter, from Professor Solomon, entitled, “Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction.” Also, Carolyn, [a] wonderful Cardiovascular News summary from Tracy Hampton, reviewing three articles. First, “Mechanisms Behind Cannabis Effects on Heart Health.” The second, “Exercise Inducible Metabolite Suppresses Hunger.” And then lastly, “Piezo1 Initiates the Cardiomyocyte Hypertrophic Response to Pressure Overload.” Dr. Carolyn Lam: Cool. There's also an exchange of letters between Doctors Jha and Borlaug on latent pulmonary vascular disease in therapeutic atrial shunt. And finally, an On My Mind, by Dr. David Kass entitled, “What's EF Got To Do, Got To Do With It.” I love it. You must read it. It's so, so cool. All right. But now, let's go on to our feature discussion, shall we? Dr. Greg Hundley: You bet, Carolyn.   Welcome listeners, to our feature discussion today, and really delving into the world of in-hospital cardiac arrest, and how we manage those patients. And we have with us today, Dr. Kevin Roedl from Hamburg, Germany, Dr. Sebastian Wolfrum from Lubeck, Germany, and our own associate editor, Dr. Mark Link from University of Texas Southwestern in Dallas, Texas. Welcome gentlemen. Kevin, we're going to start with you. Can you describe for us, some of the background information that went into the construct of your study, and what was the hypothesis that you wanted to address? Dr. Kevin Roedl: Thank you, Greg. We thank you for the kind invitation to this podcast. We're very likened to do this podcast with you. And so, talking about the background of hypothermia in-hospital cardiac arrest, we have to go back like two decades almost, because there were two studies in New England Journal of Medicine published 2002, who introduced mild therapeutic hyperthermia to the treatment in post cardiac arrest. Primary, these two studies show the benefit of the therapy in this kind of patients. And then, 2003, it was introduced in also the international guidelines. However, these studies only addressed out-of-hospital cardiac arrest patients, and also, only shockable rhythms. And so, the question arised over the years, what about other patients like non shockable rhythms, or also in-hospital cardiac arrest? And so, that's basically was the primary aim of our study to address this special population. Because when you see the states, the numbers, there are 290,000 in-hospital cardiac arrests a year. So it's actually, a very large population. And there's no randomized control trial to show any benefit, or maybe harm, in this group. There were some observational studies, 2016 in China published. From China, in this group, they looked at the Get With The Guidelines registry, and actually, they saw that there was probably a negative influence of hypothermia in the study. However, it was only observational. So actually, there were no randomized control trials. And that primary hypothesis was, that we wanted to know actually, does thus mild therapeutic hyperthermia work in this group of patients in the in-hospital cardiac arrest setting? And what is the outcome? Is it like in the out-of-hospital cardiac arrest setting, or not? Dr. Greg Hundley: Wonderful, Kevin. And so, can you describe for us then, your study population and your study design? Dr. Kevin Roedl: Yes, of course. We did a randomized control trial. There were over 1000 people screened, and overall, we included 242. So you see how hard it is to get people in there. And actually, in terms of hypothermic temperature control, we are 120 about, and long term at 118, and the final others of the endpoints. And when we look at the baseline characters of these patients, they were well balanced actually, about 72 years. When we look at the initial cardiac arrest rhythm, that's interesting because about 70% non-shockable rhythms, and 25% shockable rhythms. And probably also interesting, the location of the cardiac arrest. Medical boards about 50%, and ICU or ED was 22%. So that's probably summed up the baseline characteristics of our study. Dr. Greg Hundley: Perfect. And so Kevin, can you describe for us what was the hypothermic target for the group that was going to have their temperature recused? Dr. Kevin Roedl: Yes, hypodermic target was 32 degrees to 44. And so two degrees Celsius, basically the same target like in earlier trials. Dr. Greg Hundley: Very nice. Well listeners, now we're going to turn to our second co-author, Dr. Sebastian Wolfrum. And Sebastian, can you share with us the study results? Dr. Sebastian Wolfrum: Yes, Greg. Thank you very much for the opportunity to participate in this podcast. Only wanted to include unconscious patients, and therefore, we took a time and took 45 minutes after their cardiac arrest, to let the patients get away if they did so. We also excluded patients that had severe functional deficit before the cardiac arrest; since we could not really define the neurological outcome if we would've included those. And we didn't see any differences. Neither in mortality, not in the functional outcome, either when they're treated with 33 degrees Celsius, or whether normothermia was used. The death rate after six month was in a range which is comparable to other in-hospital cardiac arrest studies, and higher than those performed in the out-of-hospital cardiac arrest studies. It was about slightly over 70% in both groups. And the number of patients with the good functional recovery after six months was 23% of the patients in the hypothermia group, and 24% of the patients in the normothermia group. And if we look at only the survivors, we see that the ones which are worse functional outcome, were most of them dead after six months. We then also focused on the temperature curves in our patients, and to see whether we have achieved our goal. And we saw that we have reached the target temperature within four and a half hours after cardiac arrest in our hypothermia group. Which is not as fast that we had expected, but still in the range, which is comparable to other studies on this field. And we also saw that our control group was about 37 degrees, within the first 12 and 48 hours. So we truly avoided fever, which has not been done in every previous study on cardiac arrests. Dr. Greg Hundley: Very nice. And any differences between the hypothermia and normothermia groups, related to the age of the patient? Or, whether or not they had a shockable rhythm at the time of presentation? Dr. Sebastian Wolfrum: We saw as a result of our study, that age is a predictive factor for mortality. But age did not differ between our treatment groups, and therefore, did not interfere with our results. And we didn't see differences in the shockable or non-shockable rate in our patients in the different treatment groups.   Dr. Greg Hundley: Thank you. Well listeners, now we're going to turn to our associate editor, Dr. Mark Link, one of our expert electrophysiologists at Circulation. And Mark, you have many papers come across your desk, and what attracted you to this particular paper? Dr. Mark Link: There were a number of things. One, it's hard to do RCTs in resuscitation, and I thought they did a very nice job with this RCT. Two, the subject of hypothermia, or therapeutic temperature management, is a very hot one in resuscitation. It's one of the few treatments in the past that have been shown to make a difference in outcome. And so, all of those trials were done in out-of-hospital arrest. So to have a trial done in in-hospital arrest was very intriguing also. And I think we're all disappointed that it wasn't a positive trial, but we have to take the negative trials also. And I think, part of the reason it may have been a negative trial is because the normal thermic group avoided hyperthermia. And I think that's something that's coming out of a lot of these trials is avoid fever. It may not be so important to get hypothermic targets, actually, looks like it's probably not, but it looks like it's very important to avoid fever. Dr. Greg Hundley: Very nice. Well listeners, we're going to turn back to our expert panel here really, and start with you Kevin. Kevin, what do you think is the next study that needs to be performed in this sphere of research? Dr. Kevin Roedl: Thank you for this interesting question. Yeah, a bunch of studies could be performed, especially maybe in the out-of-hospital cardiac arrest study, because we don't know. This fever harmful, we have to find certain subgroups in which this treatment works. So maybe in this subgroups there is data on this and it could be a benefit. So these are, I think, the two main topics that should be done in the future. Dr. Greg Hundley: Thank you. Sebastian, what are your thoughts? Dr. Sebastian Wolfrum: As Mark said, the hypothermic treatment was, for decades, maybe the only treatment which we could give to cardiac arrest patients, which has been proven to reduce mortality. And all other studies following didn't see any be benefit of hypothermia, not even in a subgroup. Also, the TTM trials did not. So I'm questioning myself, where is the original HACA study group that benefits? Where did this hide in the other studies? So I would think, to do another study in out-of-hospital cardiac arrest patients, whether in ventricular fibrillation that had shown in the HACA trial to reduce mortality. This should be done in a similar way to the original study, to see whether there is this subgroup. People who support the idea of hypothermia also focus very much on the fast onset of their hypothermic treatment. And they say we saw a difference in mortality in the HACA trial, and we could very fast. And I think the other studies have to show that they cool as fast as the HACA study. So the main focus should be on the time calls of hypothermia after cardiac arrest, cooling very fast to a target temperature of 33 degrees, maybe holding on for 24, maybe 48 hours. Dr. Greg Hundley: Very nice, Sebastian. So focusing on the speed and the timing of that cooling. And Mark, anything to add? Dr. Mark Link: Yeah, so if I sit here with my writing group hat on for the HA and say, "What are we going to do for the resuscitation guidelines in 2025?" I think you look at the totality of the data for targeted temperature management. And I think, the main thing you say, walking away from this, is avoid fever. Don't let your patients get hot. I'm not sure you can say much more than that right now, until we get more data. Dr. Greg Hundley: Very nice. Well listeners, a really interesting provocative discussion today. And we want to thank Dr. Kevin Roedl from Hamburg, Germany, Dr. Sebastian Wolfrum from Lubeck, Germany, and our own associate editor, Dr. Mark Link from Dallas, Texas, bringing us the results of this study highlighting that hypothermic temperature control is compared with normothermia did not improve survival, nor functional outcome, at 180 days in patients presenting with coma after in-hospital cardiac arrest. Well, on behalf of Carolyn and myself, we want to wish you a great week, and we will catch you next week On The Run. This program is copyright of the American Heart Association 2022. The opinions expressed by speakers in this podcast are their own, and not necessarily those of the editors, or of the American Heart Association. For more, please visit ahajournals.org.

Dr. Peter A. McCullough, https://aapsonline.org/lawsuit-to-stop-retaliation-by-medical-specialty-boards-filed-by-aaps after years of research, is ONLY attempting to give all the data possible prior to making a decision on the stick. Dr. Peter A. McCullough is not telling anyone what to do, read the data and make the decision you feel is best. https://www.petermcculloughmd.com The bigger question is why isn't anyone at the top saying what they know they know? Dr. McCullough has broadly published on a range of topics in medicine with > 1000 publications and > 660 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald's Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster Dr. Peter A. McCullough : https://www.petermcculloughmd.com The Courage to Face COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex: https://amzn.to/3fcxkER ➔Please check out our Sponsors ➔Horome levels falling? Use MSCSMEDIA to get 25% off home test: https://trylgc.com/MSCSMEDIA Ty LetsGetChecked. ➔Fiji: https://Fijiwater.com/mscs $5 off free shipping Unleash ➔Monster Energy: https://www.monsterenergy.com/us/mscs ➔Aura: See if any of your passwords have been compromised. Try 14 days for free: https://aura.com/MSCS Thank you to Aura ➔ Stay Connected With MSCS MEDIA on Spotify Exclusive: Watch all Mscs Media Video Podcasts UNCENSORED and UNCUT.: ► https://spoti.fi/3zathAe (1st time watching a video podcast on Spotify when you hit play a settings pop-up will show, tap under the settings pop-up to watch the video playing.) ► All Links to MSCS MEDIA:https://allmylinks.com/mscsmedia

The primary demand on our health system is the management of chronic diseases. Many of these chronic diseases involve the vasculature or blood vessels such as heart disease, strokes, kidney failure, diabetes, kidney failure, etc. Renal failure is increasing in its prevalence. While filtration rate should be 100 %, the current system does not mark kidney function as poor until it drops below 60 %. We won't have symptoms of renal difficulties until are filtration rate is 30 %. We can urinate regularly even when in phase 5 of kidney failure Glycocalyx are hair like elements that line our blood vessels. The role of these hairs is to protect the blood vessel lining, serve as a gate keeper for oxygen, and to facilitate the release of nitric oxide which results in blood vessel dilation. They are the first site of damage in vessel disease. Studies have shown that improving the health of these vessels, can minimize spike protein damage, improve atherosclerosis and improve kidney function. This earliest damage to our blood vessels can be measured and effective approaches to reversing this damage are presented.

The primary demand on our health system is the management of chronic diseases. Many of these chronic diseases involve the vasculature or blood vessels such as heart disease, strokes, kidney failure, diabetes, kidney failure, etc. Renal failure is increasing in its prevalence. While filtration rate should be 100 %, the current system does not mark kidney function as poor until it drops below 60 %. We won't have symptoms of renal difficulties until are filtration rate is 30 %. We can urinate regularly even when in phase 5 of kidney failure Glycocalyx are hair like elements that line our blood vessels. The role of these hairs is to protect the blood vessel lining, serve as a gate keeper for oxygen, and to facilitate the release of nitric oxide which results in blood vessel dilation. They are the first site of damage in vessel disease. Studies have shown that improving the health of these vessels, can minimize spike protein damage, improve atherosclerosis and improve kidney function. This earliest damage to our blood vessels can be measured and effective approaches to reversing this damage are presented.

The primary demand on our health system is the management of chronic diseases. Many of these chronic diseases involve the vasculature or blood vessels such as heart disease, strokes, kidney failure, diabetes, kidney failure, etc. Renal failure is increasing in its prevalence. While filtration rate should be 100 %, the current system does not mark kidney function as poor until it drops below 60 %. We won't have symptoms of renal difficulties until are filtration rate is 30 %. We can urinate regularly even when in phase 5 of kidney failure Glycocalyx are hair like elements that line our blood vessels. The role of these hairs is to protect the blood vessel lining, serve as a gate keeper for oxygen, and to facilitate the release of nitric oxide which results in blood vessel dilation. They are the first site of damage in vessel disease. Studies have shown that improving the health of these vessels, can minimize spike protein damage, improve atherosclerosis and improve kidney function. This earliest damage to our blood vessels can be measured and effective approaches to reversing this damage are presented.

For many years, the rebuttal of the majority has been "Show me the science" on any matter of topics that reached the public eye. So, on this occasion, we present to you the man recognised as the most referenced person (in their field of expertise) in the world. After receiving a bachelor's degree from Baylor University, Dr Peter completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School. He went on to complete his internal medicine residency at the University of Washington, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. is a practicing internist, cardiologist, epidemiologist in Dallas Texas and the Chief Medical Advisor of the Truth for Health Foundation. Dr. M has broadly published on a range of topics in medicine with  1000 publications and  660 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald's Heart Disease Textbook. Dr. M is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. He is the senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. He has served as member or chair of data safety monitoring boards of 24 randomized clinical trials. Since the outset of the pandemic, Dr. M has been a leader in the medical response to the C019 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SA-RS/CoV-2 (C0VID-Nineteen) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SA/RS-C0V-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 56 peer-reviewed publications on the infection and has commented extensively on the medical response to the C0VID-nineteen crisis in TheHill, FOX NEWS Channel, NEWSMAX, OAN, ABC News, and America Out Loud Talk Radio. Dr. M testified in the US Senate Committee on Homeland Security and Governmental Affairs and in the Texas Senate Committee on Health and Human Services, US Senate Panel "CVID-Nineteen A Second Opinion," Colorado General Assembly, New Hampshire Senate, South Carolina Senate, and Pennsylvania Senate, concerning many aspects of the pandemic response.Find Dr M work here ⬇️⬇️https://www.petermcculloughmd.com/Your host is Laban M Ditchburn AKA World's Best Courage Coach. He is a speaker, critically acclaimed author and husband."I just want the truth so I can make an informed decision. " - Laban DitchburnEverything you'll ever need to know about Laban Ditchburn is found here (including his amazing book Bet on You).https://linktr.ee/LabanDitchburnSupport the show

After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School. He went on to complete his internal medicine residency at the University of Washington, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough is a practicing internist, cardiologist, and epidemiologist in Dallas Texas, and the Chief Medical Advisor of the Truth for Health Foundation.Dr. McCullough has broadly published on a range of topics in medicine with > 1000 publications and > 600 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald's Heart Disease Textbook. Dr. McCullough is a recipient of the Simon Dack Award from the American College of Cardiology and the International Vicenza Award in Critical Care Nephrology for his scholarship and research. Dr. McCullough is the founder and current president of the Cardiorenal Society of America, an organization dedicated to bringing cardiologists and nephrologists together to work on the emerging problem of cardiorenal syndromes. He is the editor-in-chief of Reviews in Cardiovascular Medicine, and senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. He has served as a member or chair of data safety monitoring boards of 24 randomized clinical trials.Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 47 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in TheHill and on FOX NEWS Channel. On November 19, 2020, Dr. McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs and throughout 2021 in the Texas Senate Committee on Health and Human Services, Colorado General Assembly, New Hampshire Senate, and South Carolina Senate concerning many aspects of the pandemic response.Support the show

In this episode, listen as Karen H. Costenbader, MD, MPH, and Brad H. Rovin, MD, answer key questions about identifying patients at high risk for lupus nephritis, whether an elevated serum creatinine always signals lupus nephritis, the safety of newer therapies for lupus in women who are pregnant or breastfeeding, and the possibility of using SGLT2 inhibitors in patients with lupus nephritis.Presenters: Karen H. Costenbader, MD, MPHProfessor of MedicineDepartment of MedicineHarvard Medical SchoolDirector, Lupus ProgramDivision of Rheumatology, Inflammation and ImmunityBrigham and Women's HospitalBoston, MassachusettsBrad H. Rovin, MDProfessor and Director, Division of NephrologyThe Lee A. Hebert Professor of NephrologyMedical Director, The Ohio State Center for Clinical Research ManagementThe Ohio State University Wexner Medical CenterColumbus, OhioReview the downloadable slidesets at: https://bit.ly/3mlHOlaLink to full program:https://bit.ly/3aC2NNL

To settle an argument, sometimes you can rely on the facts. Not anymore! Unfortunately, fact checking is not what it used to be. Fortunately, we have warriors like cardiologist Peter McCullough, MD, who are stepping out of their comfort zones and stepping into new truths. Dr. McCullough has specialized in the Interface between Renal Disease […] The post Peter McCullough, MD, John Leake, The Courage to Face IT! appeared first on LillianMcDermott.com.

Purespring Therapeutics launched in 2020 on the back of IP developed by renowned kidney researcher Prof. Moin Saleem, who spent decades working on podocytes when podocytes weren't cool. Just two years later, the company boasts three gene therapy assets and a platform developed expressly to identify new therapeutic targets to address kidney disease. These assets promise to change the "dialysis or transplant" ultimatums associated with kidney disease, where therapeutic innovation has been scarce. Under the leadership of CEO Richard Francis, the young company is operating with the audacious goal to take its therapeutics all the way to the commercial finish line. On this episode of the Business of Biotech, Francis offers a transparent look at the company's growth strategy and the progress it's achieved to date.

Juan Jimenez, MD discusses radiology contrast, risk and consent. He shares the current evidence regarding risk of contrast agents in imaging. He explores the evidence for pretreatment of a patient to reduce any risks and he offers information on who should have a risk benefit discussion with a patient when ordering imaging that uses contrast.

About This Episode: Dr. McCullough is board certified in internal medicine, cardiovascular diseases, and clinical lipidology. After receiving a bachelor's degree from Baylor University, Dr. McCullough completed his medical degree as an Alpha Omega Alpha graduate from the University of Texas Southwestern Medical School. He went on to complete his internal medicine residency at the University of Washington, cardiology fellowship including service as Chief Fellow at William Beaumont Hospital, and master's degree in public health at the University of Michigan. Dr. McCullough has broadly published on a range of topics in medicine with more than 1000 publications and more than 600 citations in the National Library of Medicine. His works include the “Interface between Renal Disease and Cardiovascular Illness” in Braunwald's Heart Disease Textbook. His works have appeared in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, British Medical Journal and other top-tier journals worldwide. He is the editor-in-chief of Reviews in Cardiovascular Medicine and senior associate editor of the American Journal of Cardiology. He serves on the editorial boards of multiple specialty journals. Dr. McCullough has made presentations on the advancement of medicine across the world and has been an invited lecturer at the New York Academy of Sciences, the National Institutes of Health, U.S. Food and Drug Administration (FDA), and the European Medicines Agency. He has served as member or chair of data safety monitoring boards of 24 randomized clinical trials. Since the outset of the pandemic, Dr. McCullough has been a leader in the medical response to the COVID-19 disaster and has published “Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection” the first synthesis of sequenced multidrug treatment of ambulatory patients infected with SARS-CoV-2 in the American Journal of Medicine and subsequently updated in Reviews in Cardiovascular Medicine. He has 35 peer-reviewed publications on the infection and has commented extensively on the medical response to the COVID-19 crisis in TheHill. On November 19, 2020, Dr. McCullough testified in the US Senate Committee on Homeland Security and Governmental Affairs concerning early ambulatory treatment of high-risk patients with COVID-19. Find out more about Dr. McCullough at: Help Dr Peter McCullough with legal IT travel cost - https://givesendgo.com/G2DR5 The McCullough report - https://www.americaoutloud.com/the-mccullough-report/ Twitter - https://twitter.com/P_McCulloughMD Pathophysiological Basis and Rationale for Early Outpatient Treatment of SARS-CoV-2 (COVID-19) Infection  - https://pubmed.ncbi.nlm.nih.gov/32771461/ Treatment algorithm for COVID-19-like and confirmed COVID-19 illness in ambulatory patients at home in self-quarantine. - https://pubmed.ncbi.nlm.nih.gov/32771461/#&gid=article-figures&pid=figure-1-uid-0 Check out our YouTube Channel: Jeremyryanslatebiz See the Show Notes: www.jeremyryanslate.com/960 Sponsors: Gusto: This episode is sponsored by Gusto. Run your payroll the easy way, the same way we do at Command Your Brand. You'll get a. $100 Amazon Gift Card just for running your first payroll! http://www.jeremyryanslate.com/gusto MyPillow: Use the promo code: CYOL to get up to 60% off https://www.mypillow.com/ Audible: Get a free 30 day free trial and 1 free audiobook from thousands of available books. Right now I'm reading " Rigged: How the Media, Big Tech, and the Democrats Seized Our Elections" by Mollie Hemingway www.jeremyryanslate.com/book  

The early stages of kidney disease are frequently managed by primary care physicians. This week on Faisel & Friends, ChenMed's National Director of Nephrology, Dr. Mufaddal Kheda discusses renal disease management in primary care.Being a doctor is your calling because you couldn't imagine doing anything else. Let's talk about your career goals in medicine. Connect with us and tell us how you dream of practicing medicine. Want to learn more about how we do healthcare? Visit our resource center and check out how we are transforming healthcare. Don't forget to subscribe to ChenMed Rx to receive the latest news and articles from ChenMed.

Show notes at pharmacyjoe.com/episode677. In this episode, I’ll discuss the efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease. The post 677: Is there an efficacy tradeoff when reducing apixaban dose in patients with end-stage renal disease? appeared first on Pharmacy Joe.

Low levels of albumin have been associated with increased mortality in patients on dialysis according to many studies. A type of protein made by the liver, albumin keeps fluid from leaking out of blood vessels while nourishing tissues and transporting hormones, vitamins, drugs, and substances like calcium throughout the body. Dr. Kam Kalantar, an expert in kidney diseases and epidemiology, joins Field Notes to explain the importance of managing albumin in patients with chronic kidney disease.

This National Donate Life Month, hear directly from a former dialysis patient and beneficiary of a kidney transplant. Bridgette Chandler, HTRN, discusses her journey coming full circle from home dialysis patient to home dialysis nurse with Fresenius Kidney Care.

Welcome to the emDOCs.net podcast! Join us as we review our high-yield posts from our website emDOCs.net. Today on the emDOCs cast with Brit Long, MD (@long_brit), we cover complications of end stage renal disease. To continue to make this a worthwhile podcast for you to listen to, we appreciate any feedback and comments you may have for us. Please let us know!Subscribe to the podcast on one of the many platforms below:Apple iTunesSpotifyGoogle Play

Last year in the U.S., home dialysis reached 14% of all treatments by Fresenius Kidney Care, and home hemodialysis with the NxStage system grew at an incredible 37%. Joe Turk, former president of NxStage Medical and current president of home and critical care therapies for Fresenius Medical Care North America, provides an inside look at how FMCNA's merger with NxStage Medical is helping evolve and grow technology for home dialysis and critical care.

When kidneys do not work, a cycle of damaging health events is started that can ultimately lead to significant bone damage for patients. Dr. Michael Anger, Chief Medical Officer of the Renal Therapies Group, joins Field Notes to discuss the methods used to prevent bone damage, preventing the need for additional and expensive therapies for patients. 

Nephrology has been under-represented in clinical research, even as we have witnessed rapid progress in precision medicine in other specialty areas. A new initiative to build the world's largest renal-focused genomic registry by Frenova, the clinical research division of Fresenius Medical Care, aims to change that. Dr. Frank Maddux, Global Chief Medical Officer, joins Field Notes to explain how this groundbreaking registry will impact the future of kidney care for years to come. 

While the distribution of COVID-19 vaccines continues across the country, the FDA has also recently granted Emergency Use Authorizations (EUA) for new monoclonal antibody therapies specifically for COVID-19 patients living with chronic kidney disease. Chance Mysayphonh, PharmD, clinical pharmacist for Fresenius Medical Care North America, joins Field Notes to discuss how these exciting new therapies will be used in Fresenius Kidney Care centers.

Throughout the COVID-19 pandemic, the work of dialysis nurses and technicians working inside hospitals and other major care facilities has been critical as a significant percentage of COVID-19 patients battle acute kidney injury. Gina Sharkey and Tana Waack, both registered nurses who work closely together as Vice Presidents of Inpatient Services at FMCNA, join Field Notes to provide a behind-the-scenes look at the front-lines inside some of the hospitals hit hardest by COVID-19. 

With the ability to provide patients greater control over their own treatment and improve their quality of life, home dialysis is a core component of the care model at Fresenius Medical Care North America. Even the federal government is pushing to see more patients treated at home. Dr. Michael Kraus, Associate Chief Medical Officer of Fresenius Kidney Care, joins Field Notes to break down the benefits of home treatment and provide insight into the company's strategy and approach. 

Health care providers throughout the world are working together to share key clinical information to improve patient quality, safety and efficiency of healthcare. Dr. Emel Hamilton joins Field Notes to share the details of how FMCNA is leading the way in improving care transitions for chronic kidney disease patients. 

How has one of the largest, leading healthcare companies in the United States responded to the COVID-19 pandemic? Dr. Jeffrey Hymes joins Field Notes to discuss how the company's efforts to prepare for a global pandemic enabled Fresenius Medical Care North America to stay ahead of the curve and keep its patients safe.